Axon Enterprise (NASDAQ:AXON) Price Target Cut to $625.00 by Analysts at The Goldman Sachs Group

Key Points

• The Goldman Sachs Group cut its price target on Axon from $720 to $625 but kept a "buy" rating—the move is one of several recent trims even as MarketBeat shows a consensus of "Moderate Buy" with an average target of $751.27.
• Axon beat expectations with $2.15 EPS (vs. $1.60 est.) and $796.7M revenue, up 38.5% year-over-year, yet the stock dropped to a 52‑week low amid legal‑risk headlines, analyst downgrades and weak macro sentiment.

Axon Enterprise (NASDAQ:AXON - Get Free Report) had its price target decreased by The Goldman Sachs Group from $720.00 to $625.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. The Goldman Sachs Group's target price would indicate a potential upside of 57.13% from the company's current price.

Several other research firms have also recently commented on AXON. Robert W. Baird set a $800.00 price target on Axon Enterprise in a report on Wednesday, February 25th. Barclays lowered their price objective on Axon Enterprise from $702.00 to $682.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 25th. Morgan Stanley dropped their target price on Axon Enterprise from $713.00 to $675.00 and set an "overweight" rating for the company in a report on Wednesday, February 25th. Northcoast Research raised Axon Enterprise from a "neutral" rating to a "buy" rating and set a $742.00 target price for the company in a research note on Tuesday, January 6th. Finally, Royal Bank Of Canada lowered their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus price target of $751.27.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON traded up $24.90 during midday trading on Wednesday, hitting $397.77. The company's stock had a trading volume of 634,187 shares, compared to its average volume of 991,810. The company has a market cap of $31.98 billion, a P/E ratio of 261.32, a price-to-earnings-growth ratio of 8.81 and a beta of 1.61. Axon Enterprise has a 12-month low of $362.73 and a 12-month high of $885.91. The business's 50 day simple moving average is $473.50 and its 200 day simple moving average is $572.61. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. During the same quarter in the prior year, the firm earned $2.08 EPS. Axon Enterprise's quarterly revenue was up 38.5% on a year-over-year basis. On average, analysts forecast that Axon Enterprise will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the completion of the sale, the chief executive officer owned 3,090,997 shares of the company's stock, valued at $1,546,240,339.28. This trade represents a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Isaiah Fields sold 2,000 shares of Axon Enterprise stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the sale, the insider owned 55,588 shares in the company, valued at $29,740,135.88. This represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,855 shares of company stock valued at $7,109,828 in the last ninety days. Company insiders own 5.70% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AXON. Newbridge Financial Services Group Inc. raised its stake in shares of Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company's stock valued at $421,000 after acquiring an additional 14 shares during the period. Vicus Capital boosted its position in shares of Axon Enterprise by 3.7% during the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company's stock worth $284,000 after purchasing an additional 14 shares during the period. Evergreen Capital Management LLC increased its holdings in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock valued at $342,000 after purchasing an additional 15 shares during the last quarter. Blue Trust Inc. increased its holdings in Axon Enterprise by 2.5% in the 3rd quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company's stock valued at $463,000 after purchasing an additional 16 shares during the last quarter. Finally, NorthCrest Asset Manangement LLC raised its position in Axon Enterprise by 5.4% in the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company's stock valued at $223,000 after purchasing an additional 16 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Morgan Stanley reiterated a constructive view highlighting AI-driven growth as a compelling entry after the pullback; analyst note frames recent weakness as a buying opportunity tied to Axon’s software/AI expansion. Axon: AI-Driven Growth Outlook Creates Compelling Entry Point After Share Pullback
• Positive Sentiment: Axon announced three new AI tools at Axon Week (Axon Vision, Axon Assistant and expanded real‑time intelligence) that could accelerate recurring software revenue and deepen product stickiness with public‑safety customers. This is the primary operational catalyst supporting upside sentiment. Axon Tackles Public Safety's Data Overload With Three New AI Tools
• Neutral Sentiment: Coverage pieces are flagging AXON as an oversold/turnaround candidate and as a play on unmanned aerial vehicle (UAV) exposure — useful framing for long‑term investors but not immediate price drivers. 2 Oversold Stocks Set for a Comeback and 1 We Brush Off
• Neutral Sentiment: AXON hit a 52‑week low, drawing attention from value/contrarian analysts — a data point that often attracts both bargain hunters and short‑term sellers. Axon stock hits 52-week low at 396.41 USD
• Negative Sentiment: Share weakness this week was driven by headlines about new legal risks tied to Axon’s HQ and related litigation, which prompted analyst price‑target cuts and increased uncertainty around expenses/legal liabilities. Axon Stock Plunged on Tuesday. Is This a Buying Opportunity?
• Negative Sentiment: Multiple outlets reported a >10% intraday decline amid analyst downgrades/price‑target trims and commentary that the stock lagged peers, which fed momentum selling. Why Axon (AXON) Shares Are Trading Lower Today
• Negative Sentiment: Broader market pressure — including rising U.S.‑Iran tensions and weaker macro data — weighed on tech and growth names, exacerbating AXON’s decline as investors fled higher‑multiple stocks. Why Axon Shares Are Sliding Tuesday?

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.